J&J VARIPURE interim data show 84.2% arrhythmia-free rate at 12 months

Johnson & Johnson -0.15% Pre

Johnson & Johnson

JNJ

234.18

234.18

-0.15%

0.00% Pre
  • Johnson & Johnson disclosed favorable 12-month interim results from VARIPURE, a real-world post-market study of its VARIPULSE pulsed field ablation platform for first-time atrial fibrillation treatment.
  • Results were presented at EHRA 2026 in Paris, with publication in Europace.
  • Data indicated durable rhythm control across patient types, with outcomes supporting broader clinical use beyond standard pulmonary vein isolation.
  • Safety findings supported a low complication profile in routine practice.
  • CE-marked labeling for VARIPULSE catheter in Europe was updated to enable ablation outside pulmonary veins, expanding addressable use in persistent atrial fibrillation workflows.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on April 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.